Nutriband (NASDAQ:NTRB) Shares Up 6.1% - Here's Why

Key Points

• Nutriband Inc. shares increased by 6.1% to a trading price of $7.15, despite a 34% decline in trading volume compared to the average.
• The company reported a quarterly EPS of ($2.12), significantly missing analysts' expectations of ($0.17), with revenue of $0.62 million versus the forecast of $0.71 million.
• US Bancorp DE acquired a new stake in Nutriband, purchasing 4,798 shares valued at approximately $29,000, indicating growing institutional interest in the stock.

Nutriband Inc. (NASDAQ:NTRB - Get Free Report) shot up 6.1% during trading on Tuesday . The company traded as high as $7.15 and last traded at $7.15. 21,094 shares were traded during mid-day trading, a decline of 34% from the average session volume of 31,957 shares. The stock had previously closed at $6.74.

Nutriband Trading Up 6.1%

The stock has a fifty day moving average of $7.10 and a 200 day moving average of $6.70. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.70 and a current ratio of 4.78. The company has a market capitalization of $86.01 million, a PE ratio of -2.49 and a beta of 1.13.

Nutriband (NASDAQ:NTRB - Get Free Report) last posted its quarterly earnings results on Tuesday, September 9th. The company reported ($2.12) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($1.95). Nutriband had a negative return on equity of 85.40% and a negative net margin of 398.29%.The business had revenue of $0.62 million during the quarter, compared to analysts' expectations of $0.71 million. As a group, sell-side analysts predict that Nutriband Inc. will post -0.6 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Nutriband stock. US Bancorp DE bought a new stake in Nutriband Inc. (NASDAQ:NTRB - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 4,798 shares of the company's stock, valued at approximately $29,000. 19.70% of the stock is currently owned by hedge funds and other institutional investors.

Nutriband Company Profile

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.